InMed Pharmaceuticals (INM) reports senior VP employee option expiration

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. reported an insider transaction by officer Eric C. Hsu, who serves as Sr. VP, Pre-Clinical Res/Dev, involving employee stock options dated 12/15/2025.

The filing shows an employee stock option labeled as an expiration covering 70 common shares, with an exercise price of $1,397.97, converted from a Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00. The option had an exercisable date of 12/16/2020 and an expiration date of 12/15/2025. Following this transaction, Hsu beneficially owned 5,280 derivative securities, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HSU ERIC C

(Last) (First) (Middle)

C/O INMED PHARMACEUTICALS INC.

1445-885 WEST GEORGIA ST.

(Street)

VANCOUVER A1 V6C3E8

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ INM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP, Pre-Clinical Res/Dev

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Expiration)	$1,397.97(1)	12/15/2025		H			70	12/16/2020	12/15/2025	Common shares	70	$0.00	5,280	D

Explanation of Responses:

1. Converted from the Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00

	/s/ Eric A. Adams, attorney-in-fact for Mr. Eric C. Hsu	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did InMed Pharmaceuticals (INM) disclose in this Form 4?

The company reported an insider transaction by Eric C. Hsuemployee stock option expiration on 12/15/2025 for derivative securities tied to common shares.

How many InMed Pharmaceuticals shares were covered by the reported option?

The reported employee stock option related to 70 common shares of InMed Pharmaceuticals Inc.

What was the exercise price of the employee stock option reported by INM?

The option had an exercise price of $1,397.97, which was converted from a Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00.

When did the reported InMed Pharmaceuticals employee stock option become exercisable and when did it expire?

The employee stock option became exercisable on 12/16/2020 and had an expiration date of 12/15/2025.

How many derivative securities does the InMed Pharmaceuticals insider hold after this transaction?

After the reported transaction, the insider beneficially owned 5,280 derivative securities, with ownership listed as Direct (D).

What is the role of the reporting person in InMed Pharmaceuticals (INM)?

The reporting person, Eric C. Hsu, is identified as an officer of InMed Pharmaceuticals Inc., serving as Sr. VP, Pre-Clinical Res/Dev.